PD166793 hydrate

C₁₇H₁₈BrNO₄S · xH₂O

412.30 (anhydrous basis)

MFCD12912437

329819997

NA.77

PD166793 is a broad spectrum, but class-selective, MMP inhibitor (low nM at MMP-2 & 3 and low μM at MMP-1, 7 & 9). Adding PD166793 to the high-fat diet substantially reduced the rise in blood glucose. The improvement of glucose homeostasis in PD166793-treated ZDF rats was a result of the enhancement of β-cell function. It prevents β-cell dysfunction and diabetes in female ZDF rats on a high-fat diet. It has been shown to block left ventricular remodeling and dysfunction in a rat model of heart failure. Preservation of normoglycemia and normal glucose tolerance in compound PD166793-treated animals is accompanied by preservation of the high serum insulin levels that are a consequence of the insulin resistance present in these animals. It is not reversing insulin resistance these animals. The most striking effect of the compound is on pancreatic insulin content and β-cell volume.

This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

100

≥98% (HPLC)

solid

Pfizer

2-8℃

O.CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c2ccc(Br)cc2)C(O)=O

1S/C17H18BrNO4S.H2O/c1-11(2)16(17(20)21)19-24(22,23)15-9-5-13(6-10-15)12-3-7-14(18)8-4-12;/h3-11,16,19H,1-2H3,(H,20,21);1H2/t16-;/m0./s1

LUKRECOTGXWIDO-NTISSMGPSA-N

5, 25 mg in glass bottle

11 - Combustible Solids

WGK 2

Eyeshields, Gloves, type N95 (US)